Agfa-Gevaert (AGFB) Q2 2025 earnings summary

Executive summary

• HealthCare IT delivered strong results in H1 and Q2 2025, driven by robust North American demand and successful cloud transition, while Digital Printing/Digital Print & Chemicals and green hydrogen segments faced subdued growth due to market softness and investment delays.

• Medical film market declined faster than anticipated, especially in China, significantly impacting Radiology Solutions and prompting further restructuring and cost-saving measures.

• Net profit reached €30 million, mainly due to a favorable AgfaPhoto arbitration award, with a €38 million non-recurring gain expected to benefit cash flow in Q3.

• A new organizational structure was announced, segmenting the business into growth and mature areas, effective January 2026, to improve management and transparency.

• A new €180 million revolving credit facility was signed, enhancing liquidity and maturing in August 2028.

Financial highlights

• Q2 2025 revenue was €281 million, down 1.6% year-over-year; H1 2025 revenue was €523 million, down 2.4%.

• Adjusted EBITDA for Q2 was €13 million (4.7% margin), down 41.2% year-over-year; adjusted EBIT for Q2 was €5 million (1.8% margin), down 58.7%.

• Free cash flow in Q2 was negative €3 million, a €37 million improvement over Q2 2024, mainly due to better working capital management and ZIRFON plant investment.

• Gross profit margin fell to 30.4% from 33.5% year-over-year.

• Net financial debt (excluding IFRS 16) increased to €85 million at end-Q2 2025, up from a positive cash position in 2023.

Outlook and guidance

• HealthCare IT is projected to maintain growth, with order intake expected to rise in the mid to high teens for FY 2025 and a shift toward more cloud-based projects, which may delay revenue recognition but increase recurring revenue stability.

• Digital Printing/Digital Print & Chemicals anticipates moderate revenue and slight profitability growth amid soft market conditions.

• Radiology Solutions will likely continue to decline, with cost-saving and restructuring measures expected to take effect in H2 2025.

• Full-year 2025 is expected to deliver positive net cash flow at the group level, supported by legal settlements and discontinued operations, though timing of some receivables remains uncertain.